India’s COVID-19 Vaccines Will Benefit Most Countries, Says Bhutan Ambassador Vetsop Namgyel

New Delhi: Bhutan’s Ambassador to India on Wednesday (December 9) said that the COVID-19 vaccines in India will benefit most countries, as they would be the easiest to administer and transport. Speaking to foreign envoys onboard a plane to New Delhi, Ambassador Vetsop Namgyel said: “Vaccines in India are the ones which will be easiest to administer and transport. Most countries will benefit from it. India is known to produce in bulk quantities, once approved it can be rolled out quickly.”

Also Read: Lack Of Adequate Cold Chain Biggest Challenge In COVID-19 Vaccine Distribution: Report

Vetsop Namgyel was among the 60 foreign heads of missions who visited the facilities of two pharmaceutical firms working on COVID-19 vaccines- the Bharat Biotech and the Biological E.

F Svane, Ambassador of Denmark to India, said that India is not working for commercial or national interest but is also working for countries around the world.

Also Read: National Expert Group On Vaccine Administration Working On Management Of COVID-19 Vaccine Roll-Out: Government

While praising Prime Minister Narendra Modi, Mahima Datla, the Managing Director of the Biological E Ltd, said it is a testament to PM Modi’s vision who’s not only showcasing collaboration but is keen to ensure that Indian companies play a vital role in delivering vaccines around the world.

Sources had informed that there is a lot of interest in India’s vaccine development efforts.

Also Read: COVID-19: Centre Consults With States/Union Territories For Cold Chain Storage Of Vaccine

PM Modi has said that India’s vaccine production and delivery capacity will be used to help all humanity in fighting this crisis.

He visited the Zydus Biotech Park in Ahmedabad, Bharat Biotech in Hyderabad, and Serum Institute of India in Pune on November 28 to conduct an extensive review of the vaccine development and manufacturing process.

Bharat Biotech had on Monday (December 7) applied for emergency use authorisation for its indigenously developed COVID-19 vaccine ‘Covaxin’ to Drugs Controller General of India (DCGI).

It is the second Indian company to apply for emergency use authorisation after the Serum Institute of India applied for such use for the vaccine developed by Oxford University and AstraZeneca.

Also Read: Six COVID-19 Vaccine Candidates In Different Clinical Trial Stage In India, Three In Pre-Clinical Stage: Union Health Secretary

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (Water, Sanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollution, waste management, plastic ban, manual scavenging and sanitation workers and menstrual hygiene.